Affiliation:
1. Department of Rheumatology and Immunology The Affiliated Changsha Central Hospital, Hengyang Medical School, University of South China Changsha China
2. Department of Orthopedic Surgery The Second Xiangya Hospital of Central South University Changsha China
Abstract
AbstractIntroductionThrombotic thrombocytopenia purpura (TTP) associated with systemic lupus erythematous (SLE), features the appearance of inhibitory autoantibodies against ADAMTS13. Rituximab and belimumab (BEL), as both targeting B cells, seem to be an optimal therapy to induce clinical remission, prevent relapse of disease and contribute to glucocorticoid induction. However, the clinical outcome of SLE‐TTP treated with sequential therapy between rituximab and BEL remain elusive.Case SeriesWe reported the clinical outcomes of 4 patients diagnosed with SLE‐TTP who were administrated a combination of corticosteroids, plasma exchange, and rituximab at stage of induction. BEL was utilized to rapidly reduce the reliance on these agents and prevent relapse of TTP at maintenance stage. Ultimately, 4 patients fully recovered with a SLE Disease Activity Index score of 0 and reached the goal at dose of prednisolone <7.5 mg/d without relapse.ConclusionSequential treatment of rituximab and BEL could be an encouraging approach in treatment of SLE‐TTP and rapid glucocorticoid reduction.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献